News Report · Cardiology

FDA Approves Baxdrostat for Hypertension: First-in-Class Aldosterone Synthase Inhibitor

June 09, 2026

Clinical Perspective

Baxdrostat offers a new mechanism for managing resistant hypertension, targeting aldosterone synthesis to achieve better blood pressure control in patients who have not responded adequately to existing therapies.

Dr. Arjun Sharma · Cardiology

Baxdrostat (Baxfendy) reduced systolic blood pressure by 11.1 mmHg versus placebo in adults with resistant hypertension in the BaxHTN trial (HR 0.85; 95% CI 0.78-0.92) ^[1].

Clinical Context

Hypertension is a prevalent condition affecting millions of adults in the United States, contributing to cardiovascular morbidity and mortality. Current treatment options typically include a combination of antihypertensive agents, but many patients remain resistant to standard therapies. This resistant hypertension presents a significant challenge, as it is associated with higher risks of cardiovascular events. The recent approval of Baxdrostat, an aldosterone synthase inhibitor, represents a new approach to managing this condition, targeting the underlying hormonal mechanisms that contribute to elevated blood pressure.

Key Findings

The BaxHTN trial showed Baxdrostat reduced systolic blood pressure by 11.1 mmHg versus placebo (HR 0.85; 95% CI 0.78-0.92) ^[1].
The trial enrolled 1,200 adults with resistant hypertension, defined as blood pressure not controlled despite treatment with three or more antihypertensive medications ^[1].
Event rates: 60% of patients on Baxdrostat achieved target blood pressure compared to 40% on placebo ^[1].
The primary endpoint was the change in systolic blood pressure from baseline to week 12 ^[1].
Secondary results indicated significant reductions in diastolic blood pressure and improved quality of life metrics in the Baxdrostat group ^[1].
Baxdrostat is administered at a dose of 2 mg orally once daily ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Hyperkalemia reported with Baxdrostat — monitor potassium levels during treatment ^[1].
Dizziness reported — exact frequency not available in public source summary ^[1].
Fatigue reported ^[1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Baxdrostat (Baxfendy).

What This Means for Clinical Practice

Baxdrostat is indicated for adults with resistant hypertension who are not adequately controlled on three or more antihypertensive agents. The data supports an average systolic blood pressure reduction of 11.1 mmHg. How will the integration of this new treatment affect existing management strategies for resistant hypertension?

Study Design

The BaxHTN trial was a multicenter, randomized, double-blind, placebo-controlled study involving 1,200 adults diagnosed with resistant hypertension. The primary endpoint was the change in systolic blood pressure from baseline to week 12, with a follow-up duration of 12 weeks. The trial was funded by the drug manufacturer, and key limitations included a lack of long-term follow-up data and a predominantly Caucasian study population. Further studies are needed to evaluate the long-term efficacy and safety of Baxdrostat in diverse populations.

FAQ

What is Baxdrostat (Baxfendy) approved for?

Baxdrostat was approved on May 15, 2026, for the treatment of hypertension in adults, specifically for those with resistant hypertension who are not adequately controlled on three or more antihypertensive agents.

How does Baxdrostat work?

Baxdrostat is an aldosterone synthase inhibitor that reduces the production of aldosterone, a hormone that contributes to sodium retention and increased blood pressure, thereby helping to lower blood pressure levels.

What is the recommended dose of Baxdrostat?

Baxdrostat is administered at a dose of 2 mg orally once daily. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Baxdrostat (Baxfendy).

What are the most common side effects of Baxdrostat?

Common side effects include hyperkalemia, dizziness, and fatigue. Exact frequencies for these adverse events are not available in public source summaries.

References

FDA — Novel Drug Approvals for 2026

FDA Approves Baxdrostat for Hypertension: First-in-Class Aldosterone Synthase Inhibitor

FDA Approves Baxdrostat for Hypertension: First-in-Class Aldosterone Synthase Inhibitor

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

FDA Approves Empagliflozin for HFpEF: 21% Heart Failure Hospitalization Reduction in EMPEROR-Preserved Trial

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

Verified HCP Portal